![Pictured: Roisin O'Cearbhaill](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/460/image/ocearbhaill-roisin.jpg?h=10d202d3)
Roisin E. O'Cearbhaill, MD
Gynecologic Medical Oncologist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Medical Treatment of Ovarian, Endometrial, and Cervical Cancers
Request an Appointment
About Me
- Research Director, Gynecologic Medical Oncology Service
- Clinical Director, Solid Tumor, Cellular Therapy Service
- Associate Attending Physician
I am a medical oncologist with a primary focus on the medical treatment of patients with gynecologic cancers. I work very closely with a team of surgeons, oncologists, and radiation therapists to determine and provide the best treatment for each patient with these diseases.
My research initiatives include improving the treatment options for women with recurrent ovarian cancer and uterine sarcomas.
A gynecologic (GY-neh-kuh-LAH-jik) oncologist is a cancer doctor with special training in the gynecologic system. This includes cervical, fallopian tube, ovarian, uterine, vaginal, and vulvar cancers.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Medical Treatment of Ovarian, Endometrial, and Cervical Cancers
Education
- MD, National University of Ireland, Galway (Ireland)
Residencies
- Mater Misericordiae University Hospital (Dublin, Ireland)
Fellowships
- Royal College of Physicians (Ireland)
- Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine (Ireland and United Kingdom)
- Medical Oncology (Ireland and Europe)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. O'Cearbhaill sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. O'Cearbhaill
- A Phase 1 Study of LYL797 CAR T Cell Therapy in People With Breast Cancer or Lung Cancer
- A Phase I/II Study of REGN4018 Given Alone or in Combination with Cemiplimab in Women with Recurrent Ovarian Cancer
- A Phase I/II Study of REGN5668 plus Cemiplimab or REGN4018 in People with Recurrent Ovarian Cancer
- Clinical Trials Co-Investigated by Dr. O'Cearbhaill
- A Phase 1 Study of Debio 0123 in People With Advanced Gynecologic Cancers
Read more
- A Phase 1B Study of E7386 and Lenvatinib in People With Advanced Endometrial Cancer
- A Phase 2 Study of Selumetinib and Olaparib or Selumetinib Alone for Ovarian and Endometrial Cancers with Certain Genetic Changes
- A Phase I Study of ALLO-647 and ALLO-316 CAR T-Cell Therapy in People with Advanced Kidney Cancer
- A Phase I/IIA Study of ATL001 with or without Pembrolizumab Immunotherapy in People with Non-Small Cell Lung Cancer
- A Phase II Study of LN-145 Immunotherapy in People with Metastatic Non-Small-Cell Lung Cancer
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. O'Cearbhaill’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Roisin E. O'Cearbhaill discloses the following relationships and financial interests:
-
2seventy bio, Inc.
Professional Services and Activities -
Aptitude Health
Professional Services and Activities -
Cancer Trials Ireland
Professional Services and Activities (Uncompensated) -
Carina Biotech
Professional Services and Activities (Uncompensated) -
Children's Medical Research Foundation (CMRF) Inc.
Professional Services and Activities (Uncompensated) -
GlaxoSmithKline
Professional Services and Activities -
GOG Foundation
Professional Services and Activities -
Immunogen
Professional Services and Activities -
Journal of the American Medical Association
Professional Services and Activities
-
Link Therapeutics
Professional Services and Activities (Uncompensated) -
Loxo Oncology
Professional Services and Activities -
Miltenyi Biotec Incorporated
Professional Services and Activities -
MJH Life Sciences
Professional Services and Activities -
OnCusp Therapeutics Inc.
Professional Services and Activities -
Regeneron Pharmaceuticals, Inc.
Professional Services and Activities -
Seagen
Professional Services and Activities -
University of Galway
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].